Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
Talia Golan(Tel Aviv University), Michael J. Hall(Université Paris Cité), David McGuinness(Université Paris Cité), Yuzhen Liu(First Affiliated Hospital of Xinxiang Medical University), Joon Oh Park(Samsung Medical Center), Teodora Goranova(AstraZeneca (United Kingdom)), Dirk Arnold(Asklepios Klinik Altona), Teresa Macarulla(Centro de Investigación Biomédica en Red de Cáncer), Daniel Hochhauser(Cancer Research UK), Hedy L. Kindler(University of Illinois Chicago), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Pascal Hammel(Université Paris Cité), Michele Reni(San Raffaele University of Rome), Philipp Schatz(AstraZeneca (Sweden)), Gershon Y. Locker(AstraZeneca (United States))
Cited by 73
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k